Back

Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Congress committee e-posters choice in pharmacology and pharmacotherapy Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Kazuma Oyama

Tohoku University, Sendai (Japan)

17 More presentations in this session

Presentation thumbnail
Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants
Mr A. Holt (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates
Mr A. Holt (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
Mr Q. Ying (Ningbo, CN)
Abstract Slides
Presentation thumbnail
Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis
Doctor M. Delbeck (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial
Assistant Professor H. Fukaya (Sagamihara, JP)
Abstract Slides

Access the full session

Session thumbnail
Congress committee e-posters choice in pharmacology and pharmacotherapy

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources